TABLE 1.
Pro-atherogenic and prothrombotic mechanisms of Lp(a)4
| Pro-atherogenic and pro-inflammatory properties of Lp(a) | Prothrombotic properties of Lp(a) |
|---|---|
| ↑ oxidized phospholipids | ↓ plasminogen activation |
| ↑ foam cell formation | ↓ fibrinolysis |
| ↑ endothelial dysfunction | ↓ tissue factor pathway inhibitor |
| ↑ smooth muscle cell proliferation | ↓ clot stability |
| ↑ monocyte chemotaxis | ↑ platelet response |
| ↑ arterial wall inflammation (IL-8, monocyte chemotactic protein, TNF-α) | ↑ plasminogen activator inhibitor-1 (PAI-1) |
TABLE 2.
| Factors increasing Lp(a) levels | Factors decreasing Lp(a) levels |
|---|---|
|
|
TABLE 3.
Lp(a) cut-off values according to different guidelines
| Recommendation | Lp(a) cut-off values |
|---|---|
| Polish Lipid Association 202120 |
|
| HEART UK consensus 20198 |
|
| European Society of Cardiology/European Atherosclerosis Society 20197 |
|

FIGURE 1.
The detailed distribution of patients by age category and sex

FIGURE 2.
The distribution of Lp(a) concentrations by age

FIGURE 3.
Results of Lp(a) concentration measurements in the studied population (divided into cardiovascular disease risk groups according to the 2021 guidelines of the Polish Lipid Association)

FIGURE 4.
Results of the survey of patients with Lp(a) > 75 nmol/l (>30 mg/dl)